|
Lee Nadler, Ph.D
Lee Nadler, M.D. is the Senior Vice President of Experimental Medicine at the DFCI, the Founder and Director of the DFCI Center for Clinical and Translational Research (CCTR), and the Dean for Clinical and Translational Research at Harvard Medical School. He built the Division of Hematologic Malignancies at the DFCI, and was chosen to be the first Chairperson of the Department of Adult Oncology at the Dana-Farber Cancer Institute and Brigham and Women’s Hospital. Further, Dr. Nadler was one of the founding leaders that built the Dana-Farber Harvard Cancer Center. The human B-cell antigens CD19, 20, 21, 22, 80 and 86 were discovered and characterized in his laboratory, and he pioneered the fields of monoclonal antibody diagnosis and therapy. His work underlies the standard of practice for leukemia and lymphoma classification throughout the world, and he was the first in the world to treat a patient with a monoclonal antibody. Dr. Nadler was appointed full professor at Harvard in 1992, and the Virginia and D.K. Ludwig Professor of Medicine in 2002. He is a member of the American Society of Clinical Investigation and American Association of Professors, and received the Rosenthal Award for the highest contributions to clinical research for an investigator under 50, in addition to being awarded the Burchenal Award for the highest contributions to clinical research and impact for an investigator over 50; only one other person has been awarded both.
|
|
Curt I. Civin - MD, ScD (honorary)
Dr. Civin is the Herman & Walter Samuelson Professor of Cancer Research in the Departments of Oncology and Pediatrics of the Johns Hopkins University School of Medicine and Co-Director of the Division of Immunology and Hematopoiesis of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. He is recognized as a worldwide leader in the treatment and research of childhood cancers, and is an internationally recognized leader and innovator in laboratory research on normal lympho-hematopoiesis, and other cancer-related research. Since 1988, Dr. Civin has led the Johns Hopkins Division of Pediatric Oncology and is the principal investigator of a National Institutes of Health (NIH) research training grant, which helps support the continued development of young investigators in the fields of cancer and blood disease research. He is board-certified in Pediatrics and Pediatric Hematology-Oncology, and has served on the editorial boards of several biomedical journals and is Editor-in-Chief of the journal, Stem Cells. Dr. Civin is inventor or co-inventor of a total 9 US patents for biomedical inventions which have emanated from his research. His current research continues to be focused on stem cells. An exciting new direction involves transducing genes into stem cells to add function to stem cells and their progeny. Dr. Civin graduated magna cum laude from Amherst College in 1970 and received his medical degree cum laude from Harvard Medical School in 1974.
|
|
Richard J. Youle, PhD
Richard Youle is the Section Chief, Biochemistry, Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke of the National Institute of Health (NIH), Bethesda, Maryland. Dr. Youle leads a research group in the study the molecular mechanisms of programmed cell death with a focus on mitochondria and therapeutic protein development. His longstanding career spanning over three decades, includes Teaching Fellow / Research Assistant, University of South Carolina, Staff Fellow / Research Chemist, Laboratory of Neurochemistry, and Research Chemist, Surgical Neurology Branch, NINDS. Dr. Youle has been awarded the Pierce Immunotoxin Award, NIH Directors Award, Mentor Award, Inventor's Hall of Fame, and has authored numerous peer-reviewed publications. Prior to becoming a senior investigator at NINDS, Dr. Youle performed postdoctoral work at the NIH. He holds a B.A. in Biology from Albion College, Michigan, and a PhD in Biology from the University of South Carolina.
|